Q3 Earnings Estimate for LENZ Issued By HC Wainwright

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at HC Wainwright issued their Q3 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Thursday, November 6th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2026 earnings at ($0.41) EPS and FY2029 earnings at $1.84 EPS.

A number of other brokerages have also issued reports on LENZ. Raymond James Financial restated an “outperform” rating and issued a $50.00 target price (up previously from $40.00) on shares of LENZ Therapeutics in a research note on Monday, October 20th. Citigroup reissued a “buy” rating and issued a $49.00 price objective (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised LENZ Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Finally, Piper Sandler upped their target price on LENZ Therapeutics to $67.00 and gave the company an “overweight” rating in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.40.

LENZ Therapeutics Stock Performance

Shares of LENZ stock opened at $22.97 on Friday. The stock’s 50-day simple moving average is $38.39 and its 200-day simple moving average is $33.83. The firm has a market capitalization of $655.15 million, a price-to-earnings ratio of -10.89 and a beta of 0.46. LENZ Therapeutics has a fifty-two week low of $16.53 and a fifty-two week high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Wednesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.08. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $4.64 million.

Institutional Investors Weigh In On LENZ Therapeutics

Hedge funds have recently bought and sold shares of the stock. Bfsg LLC acquired a new stake in shares of LENZ Therapeutics during the 3rd quarter worth approximately $30,000. Osaic Holdings Inc. lifted its stake in shares of LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after purchasing an additional 1,116 shares during the period. Tower Research Capital LLC TRC boosted its holdings in LENZ Therapeutics by 51.4% during the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after buying an additional 477 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in LENZ Therapeutics by 47.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company’s stock valued at $53,000 after buying an additional 586 shares during the period. Finally, BNP Paribas Financial Markets grew its position in LENZ Therapeutics by 93.7% during the second quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after buying an additional 944 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

Insider Buying and Selling

In related news, CFO Daniel R. Chevallard bought 2,198 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were purchased at an average cost of $22.76 per share, with a total value of $50,026.48. Following the completion of the acquisition, the chief financial officer directly owned 5,386 shares in the company, valued at approximately $122,585.36. The trade was a 68.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is currently owned by company insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.